Theravance’s First NDA Is Antibiotic Telavancin
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is seeking approval of telavancin for complicated skin and skin structure infections caused by Gram-positive bacteria.
You may also be interested in...
Theravance’s Telavancin NDA Could Get FDA Advisory Committee Review
Antibiotics for skin-structure infections could face new FDA hurdles.
Theravance’s Telavancin NDA Could Get FDA Advisory Committee Review
Antibiotics for skin-structure infections could face new FDA hurdles.
Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA
Complete response to agency will not require additional trials, but may include revising label, re-analysis of data, Theravance CEO says.